Wistar received more than $5.5 million in grants and awards from local foundations, and national and international funding agencies to support research, education and training at the Institute.
7-Aug-2018 2:45 PM EDT Add to Favorites
Patient age correlates with response to immunotherapy in melanoma and depleting regulatory T cells in young patients may have a therapeutic potential to enhance response in younger patients, according to research from The Wistar Institute.
12-Jun-2018 3:30 PM EDT Add to Favorites
The Wistar Institute and Harbour BioMed Join Forces to Advance Novel Antibody Therapies for Cancer and Infectious Diseases
Wistar and Harbour BioMed announce they have entered into a multi-year, multifaceted research collaboration to co-discover novel antibodies for the treatment of cancer and infectious diseases.
4-Jun-2018 12:05 PM EDT Add to Favorites
Wistar and Ben Franklin Technology Partners of Southeastern Pa. Forge Collaboration to Accelerate Technology Commercialization
Wistar and Ben Franklin Technology Partners of Southeastern Pennsylvania (Ben Franklin), a nonprofit conglomerate of partners providing direct/seed funding, mentorship and networks to strengthen enterprise development, have signed a Memorandum of...
27-Apr-2018 12:05 PM EDT Add to Favorites
Targeting telomerase was effective at killing NRAS-mutant melanoma cells, and the impact was further enhanced when the strategy was paired with an inhibitor of mitochondrial function, according to study results by The Wistar Institute published in...
25-Apr-2018 12:05 PM EDT Add to Favorites
Wistar Team Receives Prestigious Award from National Clinical Research Forum for DNA-based Zika Research
Wistar and partners at the Perelman School of Medicine, University of Pennsylvania; Inovio Pharmaceuticals; and GeneOne Life Science were recognized among the Top 10 Clinical Research Achievement Awards by the Clinical Research Forum for their...
19-Apr-2018 10:05 AM EDT Add to Favorites
An international team focused on HIV cure research spearheaded by The Wistar Institute in collaboration with the University of Pennsylvania and Vall d’Hebron Research Institute (VHIR) in Barcelona, Spain, established that the CD32 molecule is not...
18-Apr-2018 10:20 AM EDT Add to Favorites
Wistar researchers have found that soluble antibodies promote tumor progression by inducing accumulation of myeloid-derived suppressor cells (MDSCs) in pre-clinical cancer models.
12-Apr-2018 2:05 PM EDT Add to Favorites
see all news
Dr. Luis Montaner, Wistar Institute HIV/AIDS Expert, Can Address His Work in the Search for a Cure, for World AIDS Day
26-Nov-2013 2:25 PM EST
22-Feb-2013 4:15 PM EST
The Winter Sun May Not Be Warm, but Still Can Be Dangerous. Wistar Melanoma Expert on Wintertime UV Risks
22-Jan-2013 2:30 PM ESTsee all experts